Luminal B型乳腺癌TEC新辅助化疗疗效及影响因素分析

Analysis of the Efficacy and Influencing Factors of Neoadjuvant Chemotherapy for Luminal B Breast Cancer

目的探讨Luminal B型乳腺癌TEC新辅助化疗的疗效及其影响因素。方法对2016年1月～2018年6月于我院行4次TEC方案新辅助化疗的81例Luminal B型乳腺癌患者的临床病历资料进行回顾性分析,分析临床病理特征及相关指标的改变与疗效的相关性。结果 4周期新辅助化疗pCR率为4.94%,临床疗效与临床分期存在统计学意义(P<0.05),是否获得p CR与年龄、BMI、绝经状态、原发肿瘤大小、肿瘤部位、确诊时淋巴结状态、PR、P53、Ki67均无统计学意义(P>0.05)。而除去4例获得p CR的患者,剩余77例乳腺癌患者新辅助化疗前后ER、PR的表达状态、Ki67指数的差异具有统计学意义(P<0.05)。结论临床分期晚的患者新辅助化疗疗效相对较差,Ki67可能是乳腺癌新辅助化疗疗效的预测指标。

Objective To investigate the efficacy and influencing factors of neoadjuvant chemotherapy for Luminal B breast cancer.Methods The clinical medical records of 81 patients with Luminal B breast cancer who underwent 4 TEC regimen neoadjuvant chemotherapy in our hospital from January 2016 to June 2018 were retrospectively analyzed.The clinicopathological features and related indicators were analyzed.Correlation of efficacy.Results The p CR rate of neoadjuvant chemotherapy was 4.94%.The clinical efficacy and clinical stage were statistically significant(P<0.05).Whether pCR and age,BMI,menopausal status,primary tumor size,tumor location,and lymph node status at diagnosis were obtained.There were no significant differences in PR,P53 and Ki67(P>0.05).Except for 4 patients with p CR,the expression of ER and PR and the Ki67 index of77 patients with breast cancer before and after neoadjuvant chemotherapy were statistically significant(P<0.05).Conclusion Neoadjuvant chemotherapy is relatively ineffective in patients with late clinical stage.Ki67 may be a predictor of neoadjuvant chemotherapy for breast cancer.